"Edward is an exceptional human being who served our country bravely and we are privileged to have provided a nerve repair solution that contributed to saving his leg." Karen Zaderej, AxoGen CEO
Alachua, FL (PRWEB) July 29, 2013
AxoGen, Inc. (OTCQB: AXGN), a leading regenerative medicine company focused on the development and commercialization of products and technologies for peripheral nerve reconstruction and regeneration, today announced that Navy Corpsman Edward Bonfiglio, a patient who received limb sparing surgery utilizing AxoGen’s Avance® Nerve Graft, has been selected by the American Association of Tissue Bank’s (AATB) to represent tissue recipients on the “Donate Life” float in the 2014 Rose Parade.
During a routine foot patrol in Afghanistan, Mr. Bonfiglio’s unit was ambushed and he was shot in his left leg. Due to injury to his sciatic nerve, he lost all function and feeling below his knee. Upon returning to the U.S., surgeons at Walter Reed National Military Medical Center in Washington, D.C. presented Bonfiglio with surgical repair options that included amputation of his left leg or, as he and his family elected, repair of the severed peripheral nerve with Avance® Nerve Graft, a processed nerve allograft, with the goal of restoring function. Lt. Commander Patrick Basile, Director of Microsurgery at Walter Reed, performed the surgery that saved Bonfiglio’s leg. Today, using his own leg, Bonfiglio can walk and jog, and is currently training for the Paralympics.
Karen Zaderej, Chief Executive Officer of AxoGen, commented, “Edward is an exceptional human being who served our country bravely and we are privileged to have provided a nerve repair solution that contributed to saving his leg. He provides great inspiration and hope to patients, in particular those with nerve injuries who can benefit from our processed nerve allograft. We support his efforts to expand awareness of treatment options and the recovery process for patients with nerve injuries.”
Since 2005, the AATB has sponsored the Donate Life Rose Parade Float. The theme of the 2014 Donate Life Float, "Light Up The World," supports the organization’s mission of saving and enhancing lives through the gift of organ and tissue donation.
About the Rose Parade
The 125th Rose Parade presented by Honda themed “Dreams Come True" will take place on Wednesday, January 1, 2014 at 8:00 a.m. (PST). It will be broadcast on ABC, Hallmark Channel, HGTV, KTLA (Tribune), NBC, RFD-TV and Univision. The Parade is also seen in more than 220 international territories and countries.
About AxoGen, Inc.
AxoGen (AXGN) is a leading regenerative medicine company dedicated to advancing the science and commercialization of peripheral nerve repair solutions. The Company’s innovative approach to regenerative medicine has resulted in first-in-class products that we believe will define their product categories. AxoGen’s products offer a full suite of surgical nerve repair solutions including Avance® Nerve Graft, the only off-the-shelf commercially available processed nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa ExtraCellular Matrix (“ECM”) coaptation aid for tensionless repair of severed nerves, and AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments.
AxoGuard® Nerve Connector and AxoGuard® Nerve Protector are manufactured in the United States by Cook Biotech Incorporated, West Lafayette, Indiana, and are distributed exclusively by AxoGen. AxoGen is the parent of its wholly owned operating subsidiary, AxoGen Corporation. AxoGen’s principal executive office and operations are located in Alachua, FL.
Experience from thousands of uses of AxoGen's Avance® Nerve Graft processed nerve allograft demonstrate a range of recovered sensory and motor function from none to near complete restoration. Each patient outcome is dependent upon the nature and extent of nerve loss or damage, the timing between nerve loss and repair, and the natural course of the patient's recovery. The patient story provided reflects the experience of the particular individual and may not represent typical results.
To receive email alerts directly from AxoGen, please click here http://www.axogeninc.com/emailalerts.html.
Cautionary Statements Concerning Forward-Looking Statements
This Press Release contains “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations or predictions of future conditions, events or results based on various assumptions and management’s estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “seeks”, “estimates”, “projects”, “forecasts”, “continue”, “may”, “should”, “will” variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding product commercialization and marketing efforts for its portfolio of peripheral nerve repair products, Avance® Nerve Graft, AxoGuard® Nerve Connector and AxoGuard® Nerve Protector, product development, financial performance, sales growth, product adoption, market awareness of our products, data validation and the intent to list on a national securities exchange. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this release should be evaluated together with the many uncertainties that affect AxoGen’s business and its market, particularly those discussed in the risk factors and cautionary statements in AxoGen’s filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made, and AxoGen assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events or otherwise.